NASDAQ: DCTH May 22, 2025 Corporate Presentation Forward-Looking Statement The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potenti ...

Group 1 - Delacth has experienced strong growth for its HEPZATO treatment and trades at an attractive valuation [1] - Delacth faces both current and future competitive pressures that will likely weigh down sentiment and valuation multiples [1] Group 2 - The author identifies key information from earnings transcripts and reports that signify growth, having studied hundreds of earnings reports [2] - The author successfully identified future winners such as OPRX, OTRK, FUBO, and PLUG through careful analysis [2]

Company Overview - Delcath Systems, Inc. (DCTH) currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), suggesting favorable market performance [4] Performance Metrics - DCTH shares have increased by 0.62% over the past week, outperforming the Zacks Medical - Instruments industry, which rose by 0.37% [6] - Over the past month, DCTH's price change is 37.2%, significantly higher than the industry's 1.13% [6] - In the last quarter, DCTH shares have risen by 36.27%, and over the past year, they have gained 149.3%, while the S&P 500 has only moved 2.37% and 14.4%, respectively [7] Trading Volume - The average 20-day trading volume for DCTH is 588,239 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, one earnings estimate for DCTH has increased, while none have decreased, raising the consensus estimate from $0.28 to $0.29 [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [10] Conclusion - Given the strong performance metrics and positive earnings outlook, DCTH is positioned as a promising momentum pick for investors [12]

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Benitec Biopharma Limited (BNTC) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Benitec Biopharma Limited is a member of our Medical group, which includes 999 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 1 ...

Core Viewpoint - Delcath Systems, Inc. (DCTH) has seen a 34.5% increase in share price over the past four weeks, closing at $16.41, with analysts suggesting a potential upside of 48.7% based on a mean price target of $24.40 [1][11]. Price Targets and Analyst Estimates - The mean estimate for DCTH comprises five short-term price targets with a standard deviation of $2.97, indicating a range of estimates from a low of $21 (28% increase) to a high of $29 (76.7% increase) [2][9]. - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9]. Earnings Estimates and Market Sentiment - Analysts are optimistic about DCTH's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which have increased by 3.6% over the past month with no negative revisions [11][12]. - DCTH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, further supporting the potential for upside [13].

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

Company Performance - Delcath Systems, Inc. (DCTH) reported quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share, compared to a loss of $0.43 per share a year ago, representing an earnings surprise of -70% [1] - The company posted revenues of $19.78 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.24%, and this is a significant increase from year-ago revenues of $3.14 million [2] - Over the last four quarters, Delcath Systems has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - The sustainability of Delcath Systems' stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - The stock has lost about 3.6% since the beginning of the year, while the S&P 500 has declined by 4.3% [3] - The current consensus EPS estimate for the coming quarter is $0.08 on revenues of $19.75 million, and for the current fiscal year, it is $0.28 on revenues of $82.26 million [7] Industry Context - The Medical - Instruments industry, to which Delcath Systems belongs, is currently in the top 28% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5] - Mesa Labs (MLAB), another company in the same industry, is expected to report quarterly earnings of $2.75 per share, with revenues projected to be $63.1 million, reflecting a year-over-year increase of 7.1% [9]

Financial Data and Key Metrics Changes - The company reported a combined revenue of $19,800,000 for Hebsado and ChemoSATs in Q1 2025, with Hebsado sales in the U.S. contributing $18,000,000 and ChemoSATs in Europe adding $1,800,000, compared to $2,000,000 and $1,100,000 respectively in Q1 2024 [7][16] - Gross margins improved to 86% in Q1 2025 from 71% in the same period last year [16] - Net income for Q1 2025 was $1,100,000, a significant turnaround from a net loss of $11,100,000 in Q1 2024 [17] - Positive adjusted EBITDA was reported at $7,600,000 compared to an adjusted EBITDA loss of $7,300,000 in Q1 2024 [17] - The company ended the quarter with approximately $59,000,000 in cash and investments and no debt [8][17] Business Line Data and Key Metrics Changes - The U.S. market for Hebsado and ChemoSATs showed strong growth, with a focus on expanding treatment centers, increasing from 17 to 19 active centers [8][9] - The average treatments per center per month were approximately two in Q1, with expectations to remain just under two for the remainder of the year [10][28] Market Data and Key Metrics Changes - The European market for ChemoSATs grew by 29% over the prior quarter to $1,800,000, although it is not expected to be a significant revenue contributor in the short to medium term due to reimbursement pricing challenges [11] - The company is focusing on generating clinical data from European sites, which have over a decade of experience with ChemoSATs [11][44] Company Strategy and Development Direction - The company aims to expand its active treatment centers to 30 by year-end, with a current pace of opening three to five centers per quarter [9][10] - The strategic focus includes leveraging cash from operations to support research and development initiatives for broader patient populations suffering from liver cancer [8][15] - The company is pursuing additional indications for Hepciddo, including metastatic colorectal and breast cancer, with ongoing clinical trials [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a more even distribution of center activations throughout the year, rather than a concentration in the second half [25] - The company anticipates that the ongoing engagement with oncologists and interventional radiologists will drive demand for treatments [15] - Management acknowledged the competitive landscape but emphasized the collaborative nature of information sharing among treatment centers [38] Other Important Information - The company has implemented a patient access program to assist with copay costs and connect patients with treatment centers [10][53] - The company is managing its European operations on a breakeven basis while focusing on generating clinical data [44] Q&A Session Summary Question: Update on center activations - Management indicated that the pace of center activations may be more even throughout the year than previously anticipated, with potential for two to three additional centers in Q2 [25][26] Question: R&D expenses and EBITDA expectations - R&D expenses are expected to increase significantly, with total operating expenses projected to rise by 60% over 2024, while maintaining positive EBITDA for the year [30][31] Question: Frequency of patient treatments - The average frequency of treatments for patients is expected to remain around 4.1, which is a key driver for overall revenue [36] Question: European market growth and reimbursement - Management noted that while European revenues are increasing, reimbursement challenges remain, and they are focusing on generating clinical data before investing more resources [40][44] Question: Companion diagnostics and potential acquisitions - The company is open to exploring companion diagnostics or synergistic products but has not found suitable opportunities yet [70][72]

Financial Data and Key Metrics Changes - The company reported a combined revenue of $19.8 million for Q1 2025, with Hebsado sales in the U.S. contributing $18 million and ChemoSAT sales in Europe adding $1.8 million, compared to $2 million and $1.1 million respectively in Q1 2024 [5][15] - Gross margins improved to 86% in Q1 2025 from 71% in the same period last year [15] - Net income for Q1 2025 was $1.1 million, a significant turnaround from a net loss of $11.1 million in Q1 2024 [16] - Positive adjusted EBITDA for Q1 2025 was $7.6 million, compared to an adjusted EBITDA loss of $7.3 million in Q1 2024 [16] - The company ended the quarter with approximately $59 million in cash and investments, and positive operating cash flow of $2.2 million [16] Business Line Data and Key Metrics Changes - The company activated 19 treatment centers in the U.S. by the end of Q1 2025, with plans to reach 30 active centers by year-end [6][7] - Average treatments per center were approximately two per month in Q1, with expectations to remain just under two for the remainder of the year [8][27] Market Data and Key Metrics Changes - The European market for ChemoSAT experienced a 29% growth over the prior quarter, reaching $1.8 million, although it is not expected to be a significant revenue contributor in the short to medium term [9] - The company is focusing on expanding its presence in the U.S. market while managing reimbursement challenges in Europe [9][40] Company Strategy and Development Direction - The company aims to leverage cash from operations to support research and development initiatives for Hebsado beyond metastatic uveal melanoma patients [6] - The strategy includes expanding treatment centers and enhancing access for patients through the Hepcido KidAccess 360 platform [8] - The company is pursuing additional clinical trials for liver-dominant metastatic colorectal and breast cancer, with FDA clearance received for both trials [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the goal of 30 active centers by year-end, with a balanced approach to center activations throughout the year [22][24] - The company anticipates that the average monthly treatment per site will stabilize just under two for the remainder of the year due to the pace of new center activations [27] - Management highlighted the importance of clinical demand and engagement with oncologists and interventional radiologists in driving revenue growth [13] Other Important Information - The company has no outstanding debt obligations and has successfully raised $16.2 million through the exercise of Series F warrants [16][17] - The company is managing its European operations on a breakeven basis while focusing on generating clinical data [43] Q&A Session Summary Question: Update on center activations and expectations for Q2 - Management indicated that center activations may be more evenly distributed throughout the year than previously anticipated, with potential for two to three additional centers in Q2 [20][24] Question: Treatment frequency and center performance - Average treatment frequency is expected to stabilize around 4.1 treatments per patient, with a mix of organic and referred patients contributing to center performance [35][86] Question: R&D expenses and EBITDA expectations - R&D expenses are expected to increase significantly, with EBITDA margins projected to remain positive throughout the year despite rising operational costs [29][30] Question: European market growth and reimbursement - Management noted that while the European market is growing, reimbursement challenges remain, and additional resources will be allocated once reimbursement is secured [39][42] Question: Companion diagnostics and potential acquisitions - The company is open to exploring companion diagnostics or synergistic products but has not identified any suitable opportunities at this time [70][72]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________ FORM 10-Q ______________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 06-1245881 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 566 Queensbury Avenue Queensbury, NY 12804 (Address of principal executive offices) (518) 743-8892 (Registrant's telephone number, including area code) For t ...